Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition

@article{Graef2020ShortenedTU,
  title={Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition},
  author={Josefine Graef and Carolin Senger and Christoph Wetz and Alexander D.J. Baur and Anne Kathrin Kluge and Mathias Lukas and Julian M. M. Rogasch and Thula Cannon Walter-Rittel and David Kohnert and Marcus R. Makowski and G{\"u}liz Acker and Kai-ling Huang and Volker Budach and Holger Amthauer and Imke Schatka and Christian Furth},
  journal={Diagnostics},
  year={2020},
  volume={10}
}
Ga-68-DOTATOC-PET/MRI can affect the planning target volume (PTV) definition of meningiomas before radiosurgery. A shorter tracer uptake time before image acquisition could allow the examination of more patients. The aim of this study was to investigate if shortening uptake time is possible without compromising diagnostic accuracy and PET volume. Fifteen patients (f = 12; mean age 52 years (34–80 years)) with meningiomas were prospectively examined with dynamic [68Ga]Ga-68-labeled [DOTA0-Phe1… Expand

Figures and Tables from this paper

68Ga-DOTATOC-PET/MRI—A Secure One-Stop Shop Imaging Tool for Robotic Radiosurgery Treatment Planning in Patients with Optic Nerve Sheath Meningioma
TLDR
Ga68-DOTATOC-PET/MRI can be used for target volume contouring prior to RRS for ONSM as it enables safe treatment planning and improves diagnostic accuracy, and can be considered a safe “one-stop shop” image tool prior to radiosurgery for OnSM. Expand
Theranostics in Oncology—Thriving, Now More than Ever
TLDR
Nine original articles from around the globe provide further evidence on the use of the theranostic concept for neuroendocrine neoplasm, prostate cancer, meningioma, and neuroblastoma, as well as recently emerging targets such as the C-X-C motif chemokine receptor 4. Expand

References

SHOWING 1-10 OF 29 REFERENCES
Comparison of ⁶⁸Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results.
TLDR
Ga-DOTATOC-PET/MRI provided flawless image quality and presented an ideal combination of high sensitivity/specificity (PET) and the best possible morphological visualization of meningiomas (MRI). Expand
Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors
TLDR
Whole-body 68Ga-DOTANOC PET/MRI appears to be comparable to 68Ga/CT for lesion detection in patients with well-differentiated NETs, relative to a composite reference standard. Expand
Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI
TLDR
Ga-DOTATOC PET/CT demonstrated an improved sensitivity in meningioma detection when compared to CE-MRI, and may provide additional information in patients with uncertain or equivocal results on MRI or could help to confirm a diagnosis of menedioma based on MRI. Expand
Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.
TLDR
These data demonstrate that [68Ga]-DOTATOC-PET improves target definition for FSRT in patients with intracranial meningiomas. Expand
Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy.
TLDR
68Ga-DOTATOC-PET/CT seems to improve the target volume delineation in skull base meningiomas, often leading to a reduction of GTV compared with results from conventional imaging (MRI and CT). Expand
Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution.
TLDR
This preliminary study supports the relevance of 68Ga-DOTATOC PET/MRI as a tool for radiosurgical treatment planning of meningiomas and demonstrates a relevant impact of PET/ MRI on target volume delineation of menediomas. Expand
Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.
TLDR
The high uptake of (68)Ga-DOTA-TOC in meningiomas can be explained by the high values for vB and by the remarkably low values for k2 and k4, leading to significantly greater k1/k 2 and k3/k4 ratios and RB in menediomas than in reference tissue, and pharmacokinetic modeling offers a more detailed analysis of biologic properties. Expand
68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?
TLDR
Ga-DOTATATE PET is a reliable predictor of tumor growth in WHO grades I and II meningiomas and provides additional information to conventional cross-sectional imaging modalities and can assist in selecting the time point for treatment initiation. Expand
PET/MRI for Oncologic Brain Imaging: A Comparison of Standard MR-Based Attenuation Corrections with a Model-Based Approach for the Siemens mMR PET/MR System
TLDR
The diagnostic reading of PET/MR patients with brain tumors did not change with the chosen AC method, and quantitative accuracy of SUVs was clinically acceptable for UTE- and BD-AC for group A, whereas for group B BD was in accordance with CTref. Expand
PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.
TLDR
According to initial experiences, [68Ga]DOTATOC seems to be a very promising new PET tracer for imaging SSTRs even in small meningiomas, offering excellent imaging properties and a very high tumor-to-background ratio. Expand
...
1
2
3
...